The Platform Group AG Targets 2026 Growth with Pharma Acquisitions

The Platform Group AG (TPG) is set to expand significantly following three new acquisitions in the pharmaceutical sector. These strategic moves have prompted First Berlin Equity Research to update its assessment, maintaining a "Buy" recommendation while increasing the share price target from €19 to €20.

The acquisitions are expected to boost TPG’s sales by 16%, pushing revenue forecasts to exceed €1 billion by 2026. The adjusted AEBITDA guidance now ranges between €70 million and €80 million, driven largely by an anticipated €130 million contribution from these new deals. Despite these changes, the guidance for 2025 remains unchanged, as the transactions will not close until December.

To support these acquisitions, TPG has bolstered its 2024/28 bond by an additional €20 million, raising the total volume to €70 million. The updated projections and a revised DCF model underscore the increased price target and sustained positive outlook for the company.